Moderna, Inc. (ETR:0QF)
| Market Cap | 14.09B |
| Revenue (ttm) | 1.90B |
| Net Income (ttm) | -2.66B |
| Shares Out | n/a |
| EPS (ttm) | -6.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 35,535 |
| Average Volume | 20,354 |
| Open | 34.14 |
| Previous Close | 34.51 |
| Day's Range | 34.00 - 36.23 |
| 52-Week Range | 19.37 - 43.26 |
| Beta | 1.17 |
| RSI | 76.25 |
| Earnings Date | Feb 20, 2026 |
About Moderna
Moderna, Inc., a biotechnology company, provides messenger RNA medicines in the United States, Europe, and internationally. The company’s respiratory vaccines include spikevax, mRESVIA, COVID, RSV, seasonal influenza, combination, and pandemic influenza vaccine; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; enteric viruses include norovirus; public health vaccines consist of Zika, Nipah, and Mpox vaccines; and bacterial diseases vaccines, su... [Read more]
Financial Performance
In 2024, Moderna's revenue was $3.24 billion, a decrease of -52.75% compared to the previous year's $6.85 billion. Losses were -$3.56 billion, -24.46% less than in 2023.
Financial numbers in USD Financial StatementsNews
Arbutus Biopharma Shares Fall 19% On European Patent Revocation
(RTTNews) - Arbutus Biopharma Corp. (ABUS) saw its stock tumble after the European Patent Office (EPO) revoked one of its key lipid nanoparticle (LNP) patents, EP2279254, after years of opposition pro...
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Future Challenges
Why Moderna Inc (MRNA) May Struggle to Outperform: A Look at Future Challenges
Arbutus falls as patent dispute with Moderna hits EU snag
Arbutus (ABUS) stock sinks as the European Patent Office revokes a patent that was subject to a legal dispute between the company and Moderna (MRNA). Read more here.
This COVID-Era Biotech Favorite Is Surging Once Again On Strong Q4 Guidance: Momentum Score Spikes
Massachusetts-based Moderna Inc. (NASDAQ: MRNA) is seeing fresh momentum in recent weeks, with the stock off to a flying start in 2026. The company that rose to prominence during the COVID-19 pandemi...
Notable ETF Outflow Detected - LABU, RVMD, MRNA, KRYS
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have...
Moderna (MRNA) Increases Despite Market Slip: Here's What You Need to Know
Moderna (MRNA) closed the most recent trading day at $40.6, moving +2.52% from the previous trading session.
Noteworthy Wednesday Option Activity: ISRG, XOM, MRNA
Among the underlying components of the S&P 500 index, we saw noteworthy options trading volume today in Intuitive Surgical Inc (Symbol: ISRG), where a total of 13,598 contracts have traded so far, rep...
Moderna Stock Gets Healthy Relative Strength Rating Jump
A Relative Strength Rating upgrade for Moderna shows improving technical performance. Will it continue?
Why Moderna Stock Strength Is Only Beginning: Technical Analysis
Moderna (MRNA) Shares Surge by Nearly 13%
Moderna (MRNA) Shares Surge by Nearly 13%
Stocks making the biggest moves midday: JPMorgan, Moderna, Boeing, Cardinal Health, Chipotle & more
These are some of the stocks posting the largest midday moves.
Moderna, Kosmos Energy, Option Care Health, Kennametal And Other Big Stocks Moving Higher On Tuesday
U.S. stocks were mixed, with the Dow Jones index falling around 250 points on Tuesday. Shares of Moderna Inc (NASDAQ: MRNA) rose sharply during Tuesday's session the company provided updates on its b...
Moderna: V940/Keytruda Data And Vaccine Revenues Drive A High-Risk Recovery Story
Moderna Inc at JPMorgan Healthcare Conference Transcript
Moderna Inc at JPMorgan Healthcare Conference Transcript
Moderna, Inc. (MRNA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Monday Sector Laggards: Healthcare, Energy
In afternoon trading on Monday, Healthcare stocks are the worst performing sector, showing a 0.7% loss. Within that group, Moderna Inc (Symbol: MRNA) and Baxter International Inc (Symbol: BAX) are two...
Moderna Raises 2025 Forecast, Targets Major Vaccine And Cancer Readouts In 2026
(RTTNews) - Moderna (MRNA) heads into 2026 with stronger finances and a crowded late-stage pipeline after an aggressive cost reset in 2025 and a slate of regulatory and clinical milestones lined up fo...
Why Moderna Stock Is Dropping After Good News
Moderna Stock Jumps, Then Turns Negative: What's Happening?
Moderna shares are volatile Monday after ... Full story available on Benzinga.com
Moderna (MRNA) Projects Up to 10% Revenue Growth by 2026
Moderna (MRNA) Projects Up to 10% Revenue Growth by 2026
Moderna Stock Rises. Revenue in 2025 Will Be Higher Than Midpoint of Guidance.
Moderna also reiterates its expectations for revenue growth of up to 10% in 2026.
Moderna reiterates target of up to 10% revenue growth in 2026
Moderna expects $1.9 billion in sales, trims costs forecast for 2025
Moderna said on Monday it expects to report around $1.9 billion in sales for 2025, putting it near the upper end of its previously projected $1.6 billion to $2 billion forecast but well below reven...
Moderna, Inc.: Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings CallImproves 2025 expected GAAP operating expenses by $200 million since 3Q...
Moderna Provides Business and Pipeline Updates at 44th Annual J.P. Morgan Healthcare Conference
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings CallImproves 2025 expected GAAP operating expenses by $200 million since 3Q25 ...